Spero Therapeutics, Inc.
Spero Therapeutics, Inc. (Nasdaq: SPRO) is a clinical-stage biopharmaceutical company developing treatments for rare diseases and diseases with high unmet medical need. Its lead program is tebipenem HBr, an oral carbapenem antibiotic candidate for adults with complicated urinary tract infections, including… From the company’s description.
Over the twelve months to Jun 30, 2026, Spero Therapeutics, Inc. reported revenue of $47.00M, down 3.3% from a year earlier, and net income of $7.38M. Its operating margin was 12.8%, and operations generated $19.58M in cash. In fiscal 2025, it reported revenue of $66.80M, up 39.2% from fiscal 2024, and net income of $8.57M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Spero Therapeutics, Inc. does
In the company’s own words
Spero Therapeutics, Inc. (Nasdaq: SPRO) is a clinical-stage biopharmaceutical company developing treatments for rare diseases and diseases with high unmet medical need. Its lead program is tebipenem HBr, an oral carbapenem antibiotic candidate for adults with complicated urinary tract infections, including pyelonephritis, caused by certain microorganisms. The candidate completed a Phase 3 trial that met its primary endpoint, and GSK submitted a New Drug Application resubmission to the FDA in December 2025. Under an exclusive license, GSK is responsible for further development, regulatory filings and commercialization in most territories; Meiji Seika Pharma retains rights in Japan and certain other Asian countries. Spero receives potential milestone payments and royalties under these arrangements. The company has ceased development of its other principal candidates, SPR206, for resistant bacterial infections, and SPR720, for nontuberculous mycobacterial pulmonary disease. Spero has no products approved for sale and has not generated revenue from product sales. It was founded in 2013 and focuses its resources on tebipenem HBr and other corporate activities.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- CAMBRIDGE, MA
- Fiscal year end
- December
- CIK
- 1701108
- SIC
- 2834
Financial performance, year by year
Fiscal 2017–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Spero Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Spero Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Spero Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Spero Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Spero Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”